Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Halozyme Therapeutics

Biotech & Life Sciences · San Diego, United States · Founded 1998 · IPO 2004 Unicorn

Halozyme Therapeutics develops extracellular matrix targeting products for the insulin, cancer, dermatology and drug delivery markets

Valuation
$9.54B
Market cap · May/2026
Revenue
$1.40B
Latest reported FY
EBITDA
$1.15B
Latest reported FY

Investors

1 investor on Halozyme Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Artiman Ventures

Global footprint

Where Halozyme Therapeutics has talent and traffic

Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown
Web traffic by country
11K monthly visits
across markets
🇺🇸 United States51.8%
🇬🇧 United Kingdom20%
🇪🇸 Spain17.3%
🇨🇦 Canada10%
🇮🇳 India1.8%
Top 5 markets shown

Capital deployed

Halozyme Therapeutics's 3 investments and acquisitions.

Every disclosed deal where Halozyme Therapeutics appeared as a backer or acquirer, 2022–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Halozyme Therapeutics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Halozyme Therapeutics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Halozyme Therapeutics

        An AI-synthesized read of the highest-engagement posts about Halozyme Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Halozyme Therapeutics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.